Vertex Pharmaceuticals Q2 2025 Earnings Report Highlights Revenue Growth and Product Launch Progress
Vertex Pharmaceuticals (VRTX) reported Q2 2025 revenue of $2.96 billion, a 12% year-over-year increase, driven by strong U.S. and international growth in its cystic fibrosis therapies and early contributions from new products like CASGEVY and JOURNAVX. The company also provided updates on the launch of its therapies in multiple regions and the progress of patient treatments.
Tickers: $VRTX
Topics: earnings report financial performance pharmaceuticals product launch revenue growth